Organization
Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology
10 abstracts
Abstract
Efficacy and safety of mecapegfilgrastim in preventing neutropenia during concurrent chemoradiotherapy.Org: The First Affiliated Hospital of Air Force Military Medical University, Affiliated Hospital of Yangzhou University, Taixing People's Hospital, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology,
Abstract
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.Org: Fujian Cancer Hospital, First Chest Radiotherapy Department, Hunan Cancer Hospital, Changsha, China, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Department of Melanoma Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China, The Third People's Hospital of Zhengzhou,
Abstract
Effect of first-line bevacizumab on prognosis of second or later-line immunotherapy in patients with advanced non-squamous non-small cell lung cancer: A retrospective analysis.Org: Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan YZY Biopharma, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Qilu Hospital of Shandong University, Jinan,
Abstract
PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).Org: Fudan University Shanghai Cancer Center, Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Breast Oncology, Peking University Cancer Hospital, Harbin Medical University Cancer Hospital,
Abstract
A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital, Shenyang, China, Liaoning Cancer Hospital and Institute, Shenyang, China,
Abstract
Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi City,
Abstract
SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.Org: Sichuan Kelun-Biotech Biopharmaceutical, Collaborative Innovation Center for Cancer Medicine, Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tongji Medical College Huazhong University of Science and Technology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, College of Biomedicine and Health,
Abstract
A study to evaluate the safety, tolerability, and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1–selected non–small-cell lung cancer (NSCLC): Updated efficacy and safety results.Org: Harbin Medical University Cancer Hospital, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Beijing Chest Hospital,Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, West China Hospital, Sichuan University, Nanjing Drum Tower Hospital,
Abstract
KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Oncology Department, the First Affiliated Hospital of Xinxiang Medical College, Chongqing University Three Gorges Hospital & Chongqing Three Gorges Central Hospital, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tianjin Medical University Cancer Institute & Hospital,National Clinical Research Center for Cancer,